Anti-Cancer Drug Nab-Paclitaxel May Exacerbate Corneal Epithelial Disorder

Yuka Hosotani*, Hiroto Ishikawa, Kumiko Miyanaga and Fumi Gomi
Hyogo College of Medicine, Nishinomiya, Japan

Abstract

Purpose: To report 2 cases of corneal disorder after cancer treatment with nab-paclitaxel.

Methods: Retrospective review of 2 cases.

Case presentation: Case 1 was a 55-year-old female who presented with blurred vision. She underwent cancer treatment in the form of combination therapy with nab-paclitaxel, trastuzumab, and pertuzumab for breast cancer 2 weeks before. An ophthalmoscopic examination showed an atypical corneal epithelial invasion in both eyes. The corneal disorder was resolved following discontinuation of nab-paclitaxel. Case 2 had a pancreatic cancer and was presented with an atypical corneal epithelium invasion in both eyes after treatment with S-1 and gemcitabine hydrochloride. The corneal disorder might be caused by S-1, so S-1 treatment was replaced by nab-paclitaxel. The corneal disorder improved temporarily, but it worsened 3 months after the administration of nab-paclitaxel. Finally, the corneal disorder was resolved following the discontinuation of nab-paclitaxel as well as in case 1.

Conclusion: Our 2 cases suggest that cancer treatment including nab-paclitaxel may cause severe corneal disorders. Clinicians should consider the possibility of the corneal disorder being caused by the cancer therapy.

Keywords: Nab-paclitaxel; Corneal epithelial disorder; Anti-cancer agent; S-1

Introduction

Ocular side effects induced by systemic anti-cancer drugs are common, but less attention is being paid to them, especially ocular surface disorders.

Nanoparticle albumin-bound (nab-) paclitaxel (ABRAXANE; Abraxis BioScience, Los Angeles, CA, USA) is a taxane-type chemotherapy medicine used to treat various malignancies, such as breast, pancreatic, gastric and non-small-cell lung cancer [1]. Major systemic complications caused by nab-paclitaxel is myelosuppression and peripheral neuropathy. Cystic macular edema is also a known side effect of affecting vision. [2]

Previously, we had reported a case with corneal epithelial disorder caused by nab-paclitaxel [3]. We recently met another case, so corneal disorder may not be a rare side effect induced by this drug. Therefore, in the present study, we report the details of both cases and review cancer drug-induced corneal disorder.

Case Report

Case 1

The corneal epithelial disorder in case 1 had been reported briefly after a short follow-up period [3]. This case was a 55-year-old female who presented with blurred vision bilaterally. Best corrected visual acuity (BCVA) was 20/60 in the right and 20/40 in the left eye. She underwent combination therapy of cancer treatment with nab-paclitaxel, trastuzumab, and pertuzumab for 2 weeks before. An ophthalmoscopic examination showed an atypical corneal epithelial invasion in both eyes. The corneal disorder was resolved following discontinuation of nab-paclitaxel. BCVA was recovered to 20/15 in the right and 20/20 in the left eye respectively 4 months after the discontinuation [3]. However, the breast cancer worsened and the same therapy including nab-paclitaxel was restarted. Two months after restarting a treatment, similar corneal epithelial disorder was recurrent in both eyes. The vision of each eye was not deteriorated because lesions were localized in the upper cornea but they still remained for more than 3 months under the continuous administration of nab-paclitaxel (Figure 1).

Case 2

A 70-year-old female presented with blurred vision. BCVA was 20/27 in right and 20/50 in left eye. An ophthalmoscopic examination showed an atypical cornneal epithelium invasion in both eyes (Figure 2a). She had been treated with gemcitabine hydrochloride (1000 mg/m²) and S-1 (40 mg/day to 80 mg/day) for pancreatic cancer for 3 years before. We considered that the corneal disorder might have been caused by S-1, then withdrew the S-1 and nab-paclitaxel (125 mg/m²) was administrated instead with the treatment of preservative-free artificial tear and started combination therapy with nab-paclitaxel, trastuzumab and pertuzumab.

Figure 1: Patient’s demographic profile.

*Corresponding author: Yuka Hosotani, Hyogo College of Medicine, Nishinomiya, Japan, Tel: +81-798-45-6462; Fax: +81-798-45-6464; E-mail: y-hoso@hyo-med.ac.jp

Received July 13, 2017; Accepted August 13, 2017; Published August 20, 2017


Copyright: © 2017 Hosotani Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Table 1: Summary of available treatment for corneal adverse effects of anti-cancer drugs.

<table>
<thead>
<tr>
<th>Agent</th>
<th>Reference</th>
<th>Patients number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nab-paclitaxel</td>
<td>Hosotani Y et al. [3]</td>
<td>1</td>
</tr>
<tr>
<td>Trastuzumab</td>
<td>Tsuda M et al. [8]</td>
<td>1</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>Hori Y et al. [6]</td>
<td>1</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>Nguyen AT et al. [9]</td>
<td>2</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>Lee HS et al. [10]</td>
<td>1</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>Goto M et al. [11]</td>
<td>1</td>
</tr>
<tr>
<td>Capecitabine</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Perifosine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gefitinib</td>
<td>Ho WL et al. [7]</td>
<td>Review</td>
</tr>
</tbody>
</table>

Each cancer drug used in case 1 had a potential for inducing corneal disorder. The adhesion of corneal epithelium cells might get weakened by using trastuzumab emtansine. Thus, the cancer treatment involving trastuzumab, pertuzumab and nab-paclitaxel might cause a corneal disorder.

**Conclusion**

After long-term use of agents that might have negative effects on the corneal epithelium, we conclude that this combination therapy strongly affected the corneal proliferation and differentiation, resulting in a defect of the corneal epithelium cells. Thus, the improvement of corneal disorder following discontinuation of nab-paclitaxel suggested that nab-paclitaxel was a major factor of the anti-cancer drug-induced corneal epithelial disorder. After the restart of nab-paclitaxel, the recurrence of corneal disorder was observed. The fact reinforces our hypothesis; nab-paclitaxel may cause the corneal epithelial disorder.

In case 2, the cancer treatment included gemcitabine, S-1 and nab-paclitaxel. The corneal disorder resolved firstly following the discontinuation of S-1. The recurrent corneal disorder after nab-paclitaxel administration finally resolved following its discontinuation, suggesting that the corneal disorder might be caused by S-1 and nab-paclitaxel mainly but not gemcitabine. Also, there is no report of gemcitabine-induced corneal disorder. Previous report suggested that S-1 could cause damage to the corneal limbal stem cells (CLSCs) [12]. Although there was no corneal limbal stem cell deficiency clinically, over 3 years of use of S-1 might have a significantly negative effect on CLSCs. Therefore, the recurrent corneal disorder after nab-paclitaxel administration occurred due to the CLSCs fragility following long-term use of S-1.

Concerning the ophthalmoscopic examination, our 2 cases showed the same pattern of abnormal corneal epithelial cells invading from the limbs, suggesting that CLSCs might be affected by nab-paclitaxel.

Recent reports support the effectiveness of cancer therapy consisting
of a combination of several anti-cancer agents [13,14]. S-1 is being used increasingly as an adjuvant in general and nab-paclitaxel is used after S-1 such as case 2. In our 2 cases, the causative mechanism of the corneal disorder is considered to be an involvement of nab-paclitaxel directly or the combination cancer therapy involving nab-paclitaxel.

The incidence rates and the timing of development of corneal disorder induced by the cancer therapy including nab-paclitaxel is still unknown. Such disorder can affect vision from several months to several years since the initiation of the therapy. Therefore, we ophthalmologists should consider the association of the cancer drug when examining the case with corneal disorders of uncertain etiology and also check the cornea carefully whenever we examine patients with cancer, especially if they are treated with a combination cancer therapy. In addition, oncologists should be aware of this possible side effects caused by drugs administered systemically and instruct patients to consult ophthalmologists.

References